Colorectal cancer is the third most diagnosed type of cancer worldwide. Up to 80% of the cases are related to environmental ...

Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y22 ...

Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumorsInterim analysis from ...

About PMV Pharma PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. TP53 mutations are found in ...

Work at Scorpion Therapeutics Inc. has led to the identification of cellular tumor antigen p53 (TP53) (Y220C mutant) activators reported to be useful for the treatment of cancer.

Researchers sought to determine whether combination therapy with zanubrutinib, obinutuzumab, and venetoclax would be effective for TP53-mutant MCL.

Karyopharm Therapeutics reported a mixed financial performance for Q1 2025, with revenue falling short of expectations at $30 million against a forecast of $37.84 million. Despite this, the company’s ...